{
}
Barclays has expressed strong confidence in Sanofi, maintaining an 'overweight' rating and setting a price target of 125 euros, anticipating group net sales of 9.61 billion euros for Q1 2025. The optimism is fueled by Sanofi's direct-to-consumer campaign for Dupixent targeting COPD and upcoming product launches, which are expected to enhance market momentum. Sanofi's strategic vaccination approach and regulatory navigation further underscore its commitment to stable growth.
Sanofi shares are poised for a breakout, currently testing resistance at EUR 106.66, with a target of EUR 137.00 if the price surpasses EUR 110.00. Analysts largely recommend buying, with an average target of EUR 117.77, and the stock benefits from a favorable seasonal trend, historically rising 8.3% until the end of May.
UBS has named Roche as its preferred Swiss pharmaceutical stock, upgrading its rating to "Buy" and raising the target price from CHF 300 to CHF 338. The firm cites Roche's sustainable growth, driven by strong performances from Vabysmo and Ocrevus, and anticipates significant sales increases from ongoing development projects, including Ocrevus HD and Trontinemab. While Roche's earnings per share growth is projected at 8.1% from 2024 to 2029, slightly below the industry average, UBS remains optimistic about the company's long-term potential and cash flow for acquisitions.
UBS has maintained a "Buy" rating for Sanofi, setting a target price of 120 euros. Analyst Jo Walton highlighted that the future of Sanofi's immunology products will be influenced by the discussion surrounding copycat drugs for Dupixent expected around 2030, countering skepticism about their medical applications.
UBS has upgraded SANOFI to a 'Buy' rating, indicating a positive outlook for the stock. However, the information provided is for informational purposes only and does not constitute a recommendation to buy or sell. Investors are reminded of the risks involved in purchasing securities, which may lead to total capital loss.
Sanofi, Europe's leading pharmaceutical group, generates 70.6% of its sales from pharmaceutical products, with specialty medicine accounting for 59.3%. The company also focuses on human vaccines (17.4%) and consumer healthcare products (12%). By the end of 2023, Sanofi will operate 54 production sites globally, with significant sales in the United States (43%) and Europe (18.6%).
UBS has maintained a 'Buy' rating for Sanofi, setting a target price of 120 euros. Analyst Jo Walton highlighted that the future of Sanofi's immunology products will be influenced by the discussion surrounding copycat drugs for Dupixent expected around 2030, countering skepticism about their medical applications.
UBS has maintained a 'Buy' rating for Sanofi, setting a target price of 120 euros. Analyst Jo Walton expressed optimism regarding the upcoming launches of Dupixent for COPD and Tolebrutinib for smoldering MS following a recent management call.
UBS has upgraded SANOFI to a 'Buy' rating, indicating a positive outlook for the stock. However, the information provided is for informational purposes only and does not constitute a recommendation to buy or sell securities. Investors are reminded of the risks involved, including the potential total loss of capital.
UBS has reaffirmed its "Buy" rating for Sanofi, setting a target price of 120 euros. Analyst Jo Walton expressed optimism regarding the upcoming launches of Dupixent for COPD and Tolebrutinib for smoldering MS, following a recent management call. As of February 3, 2025, Sanofi's stock was trading at 104.38 euros, reflecting a slight increase of 0.19%.
Sanofi
Companies
| Symbol | SNY |
| Name | Sanofi |
| Currency | USD |
| Sector | Health Care |
| IndustryGroup | Pharmaceuticals, Biotechnology & Life Sciences |
| Industry | Pharmaceuticals |
| Market | NASDAQ Global Select |
| Country | France |
| State | |
| City | Paris |
| Zipcode | 75008 |
| Website | http://www.sanofi.com |
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
barclays optimistic on sanofi's growth ahead of 2025 market targets
15:52 01.04.2025
Sanofi shares poised for breakout amid favorable analyst outlook and seasonality
14:40 18.03.2025
ubs upgrades roche to preferred pharmaceutical stock with strong growth potential
United States Dollar
Euro
Swiss Franc
Nestlé S.A.
Sanofi
Hoffmann-La Roche AG
Novartis AG
CHE
Show more
12:00 13.02.2025
ubs maintains buy rating for sanofi with target price of 120 euros
09:58 13.02.2025
ubs upgrades sanofi to buy amid investment considerations and risks
09:58 13.02.2025
sanofi maintains strong market position with diverse pharmaceutical and vaccine offerings
09:46 13.02.2025
ubs maintains buy rating for sanofi with target price of 120 euros
09:46 13.02.2025
UBS maintains buy rating for Sanofi with target price of 120 euros
12:48 03.02.2025
ubs upgrades sanofi to buy amid investment considerations and risks
12:48 03.02.2025
ubs maintains buy rating on sanofi with target price of 120 euros
11:48 03.02.2025
Trending
Subcategory
Countries:
Companies:
Currencies:
People: